DR. LEE DAI WEE
Department of Oncology Clinical
Faculty of Medicine
david.leeum.edu.myView CV | |
Publons | |
Scopus Link | |
Biography | |
Dr David Lee Dai Wee is a consultant clinical oncologist at the University of Malaya Medical Centre and lecturer at the Faculty of Medicine, University of Malaya. He received his undergraduate medical education at International Medical University (IMU), Malaysia, and subsequently Master of Clinical Oncology at the University of Malaya in 2020. Dr Lee also holds FRCR (Clinical Oncology) since 2022. He completed a fellowship in experimental therapeutics under guidance of Dr Daniel Tan at the National Cancer Centre Singapore, involving in the conduct of more than 40 early-phase clinical trials. He is the principle investigator for various international multicenter clinical trials, focusing on early-phase studies, thoracic cancers, and head and neck cancers. Dr Lee is the inaugural recipient of the American Society of Clinical Oncology (ASCO) Leadership Development Program - Asia Pacific award in 2021-2022. He received the ASCO International Development and Education Award (IDEA) in 2024, and IASLC Academy Award 2024. Currently Dr Lee serves in the ASCO Membership Advisory Group, IASLC Multidisciplinary Clinical Science Committee and FARO Council. |
Publication
Finance
Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with oncogene-addicted metastatic non-small-cell lung cancer
Implementation of hippocampal sparing whole brain radiotherapy in a resource-limited setting.
Maintaining a national essential medicine list for cancer in Malaysia: Where do we stand?
DOCETAXEL-INDUCED FEBRILE NEUTROPENIA IN BREAST CANCER PATIENTS IN MALAYSIA
Implementation of hippocampal sparing whole brain radiotherapy in a resource-limited setting.
Creating a cancer advocacy program in Indonesia
Circulating tumour DNA (ctDNA) burden quantified through low-pass whole genome sequencing as an early pharmacodynamic biomarker of therapeutic response in patients enrolled on phase 1 trials.
Maintaining a national essential medicine list for cancer in Malaysia: Where do we stand?